H.C. Wainwright analyst Sara Nik reiterated a Buy rating on Cantargia AB today and set a price target of SEK14.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sara Nik’s rating is based on the strategic focus of Cantargia AB on its core pipeline, particularly in pancreatic ductal adenocarcinoma (PDAC) and autoimmune indications. Despite the lack of success in the TRIFOUR study for triple-negative breast cancer (TNBC), this outcome does not affect the company’s broader research and development efforts, which are centered on areas with distinct biological characteristics and promising potential.
Furthermore, the market’s negative reaction to the TRIFOUR study results is seen as disconnected from the fundamental value of Cantargia’s ongoing projects. The analyst emphasizes that the failure in TNBC is specific to that indication and does not predict outcomes in PDAC and non-small cell lung cancer (NSCLC), where the company has a more defined strategy. With the anticipation of advancing clinical studies in these areas, the Buy rating reflects confidence in the company’s future prospects and its ability to deliver value through its diversified pipeline.
According to TipRanks, Nik is a 5-star analyst with an average return of 66.9% and a 38.89% success rate. Nik covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Moleculin Biotech, and Cantargia AB.